Share on StockTwits
 

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell sold 11,790 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $154.50, for a total value of $1,821,555.00. Following the completion of the transaction, the chief executive officer now directly owns 963,276 shares of the company’s stock, valued at approximately $148,826,142. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on ALXN shares. Analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday. They now have a $170.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Alexion Pharmaceuticals from $150.00 to $185.00 in a research note to investors on Friday, January 31st. Finally, analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals from $106.00 to $145.00 in a research note to investors on Friday, January 31st. They now have a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $153.67.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.10% on Wednesday, hitting $154.49. The stock had a trading volume of 1,416,879 shares. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $169.98. The stock’s 50-day moving average is $137.4 and its 200-day moving average is $120.4. The company has a market cap of $30.346 billion and a P/E ratio of 123.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, January 30th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. On average, analysts predict that Alexion Pharmaceuticals will post $3.87 earnings per share for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.